Chronic Myeloproliferative Neoplasias

AKT is a therapeutic target in myeloproliferative neoplasms

Article metrics


The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K and ERK signaling pathways. JAK inhibitors by themselves are inadequate in producing selective clonal suppression in MPN and are associated with hematopoietic toxicities. MK-2206 is a potent allosteric AKT inhibitor that was well tolerated, including no evidence of myelosuppression, in a phase I study of solid tumors. Herein, we show that inhibition of PI3K/AKT signaling by MK-2206 affected the growth of both JAK2V617F- or MPLW515L-expressing cells via reduced phosphorylation of AKT and inhibition of its downstream signaling molecules. Moreover, we demonstrate that MK-2206 synergizes with ruxolitinib in suppressing the growth of JAK2V617F-mutant SET2 cells. Importantly, MK-2206 suppressed colony formation from hematopoietic progenitor cells in patients with primary myelofibrosis and alleviated hepatosplenomegaly and reduced megakaryocyte burden in the bone marrows, livers and spleens of mice with MPLW515L-induced MPN. Together, these findings establish AKT as a rational therapeutic target in the MPNs.


The BCR-ABL negative myeloproliferative neoplasms (MPNs) are among the most common hematological malignancies in the United States with a prevalence of at least 130 000–150 000.1 MPNs, including polycythemia vera, essential thrombocythemia and primary myelofibrosis (PMF) arise in genetically transformed hematopoietic stem cells that retain the capacity for multilineage differentiation and effective myelopoiesis. In 2005, a novel activating mutation involving the Janus kinase 2 gene (JAK2), which resulted in expression of the V617F-activated mutant, was identified in a substantial fraction of patients with all three subtypes of MPNs.2, 3, 4, 5, 6 This discovery led to significant developments in the diagnosis of MPNs and the advent of novel therapies.7, 8

JAK2V617F as well as exon 12 mutant alleles seen in JAK2V617F-negative MPN lead to enhanced JAK2 kinase activity and cytokine-independent growth of primary cells and cell lines. Mutations in JAK2 are associated with the vast majority of cases of polycythemia vera and up to 50% of patients with essential thrombocythemia and PMF.9 Sequencing of cytokine receptors in MPN patients lacking a JAK2 mutation led to the discovery of somatic mutations at codon 515 of the thrombopoietin receptor (MPLW515L) in essential thrombocythemia (8% of patients) and PMF (10–15% of patients).10, 11 Similar to the JAK2V617F mutation, expression of MPLW515L leads to cytokine-independent growth of murine and human hematopoietic cells and constitutive activation of the JAK/STAT pathway.10 In a murine retroviral transplant model, MPLW515L resulted in abnormal megakaryocyte expansion and myelofibrosis (MF),10 in contrast to the polycythemia vera phenotype seen in recipients of JAK2V617F-transformed hematopoietic cells.12, 13, 14, 15 It should be noted that no significant differences in overall or leukemia-free survival was noted among JAK2-mutated MPL-mutated, or JAK2/MPL-unmutated patients.16 Apart from mutations in JAK2 and MPL, MPN cells harbor mutations in TET2, ASXL1, SF3B1, EZH2, IDH, DNMT3a among others, and that the presence of some of these mutations affect outcome.17, 18, 19, 20

Until very recently, management strategies for the MPNs were largely empiric, and depending on the phenotype consisted of antiplatelet therapy, phlebotomy, hydroxyurea, androgens, anagrelide, immunomodulatory agents, erythropoietin-stimulating agents and interferon-α. Recently, the Food and Drug Administration approved the small molecule ruxolitinib as the first oral JAK inhibitor in patients with MF. In clinical trials, ruxolitinib reduced splenomegaly and improved constitutional symptoms, however, was associated with the development of anemia and thrombocytopenia in a significant subset of MF patients.8, 21 A number of other JAK inhibitors are in varying stages of preclinical and clinical development.22, 23 Whereas as a group, JAK inhibitors suppress kinase activity in vitro, they show varying effects on JAK2 mutant allele burden in patients and none has been shown to eliminate the malignant clone in an animal model of MPN15 or in patients. Thus, although JAK inhibitors provide relief of many MPN-associated pathologies, they are not curative and should be used in a select group of MF patients whose symptoms justify the need for JAK inhibitor therapy.24

Although much of the research to date has focused on the activation of JAK/STAT signaling in MPN patients, other pathways downstream of the class I cytokine receptors, including PI3K/AKT are also prominently activated in JAK2V617- and MPLW515L-induced MPNs.10, 25, 26, 27, 28, 29 Of note, dependence of tumor cells on PI3K/AKT signaling has been observed in several oncogenic networks. For example, the PI3K/AKT pathway is required for BCR-ABL-induced leukemia in animal models of Ph+ B-ALL.30 Moreover, PI3K/AKT/mTOR inhibitors have been shown to effectively and selectively target MPN cells,31, 32 leukemia cells33, 34 and solid tumors in preclinical and/or clinical studies.35, 36

Here, using MPN cell lines and patient specimens, we show that inhibition of PI3K/AKT signaling with the selective AKT inhibitor MK-2206 induces proliferative arrest and apoptosis of MPN cells in vitro and reduces MPN tumor burden in vivo. We also demonstrate that MK-2206 and ruxolitinib cooperate to suppress the growth of SET2 cells that harbor the JAK2V617F mutation, suggesting that combining these two agents represents a rational therapeutic strategy for MPNs with sufficient rationale to support clinical investigation.

Materials and methods


MK-2206, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-1,2,4-triazolo(3,4-f) (1,6)naphthyridin-3(2H)-one hydrochloride (1:1), was generously provided by Merck (Rahway, NJ, USA). For in vitro experiments, 10 μM stock solutions of MK-2206 were formulated in dimethyl sulfoxide and subsequently diluted in Roswell Park Memorial Institute-1640 media for HEL and SET2 cells. All other compounds were purchased from either Sigma (St Louis, MO, USA) or Calbiochem (San Diego, CA, USA). Antibodies used for western blotting included phosphorylated and total AKT, PRAS-40 and BAD (Cell Signaling, Danvers, MA, USA).

Cell lines and retroviral transduction

HEL and SET2 cells37 were grown in Roswell Park Memorial Institute-1640 with 10% fetal bovine serum. 293T cells were grown in Dulbecco’s modified Eagle medium with 10% fetal bovine serum. Transient transfection of 293T cells and generation of retroviral supernatant were performed using Fugene (Promega, Madison, WI, USA) according to manufacturer’s guidelines.

Analysis of growth, cell cycle and apoptosis

Logarithmically growing cells were seeded in a 48-well plate and exposed to the designated concentrations of MK-2206 for 48 h and viable cells were quantified by trypan blue staining. Values were transformed to percent inhibition relative to vehicle control (0.1% dimethyl sulfoxide) and the 50% effective concentration curves were fitted according to nonlinear regression analysis of the data using PRISM GraphPad (GraphPad Software, La Jolla, CA, USA). For proliferation assays, cells were labeled with 30 μg/ml bromodeoxyuridine for 30 min, fixed with 2% paraformaldehyde for 10 min at room temperature, permeabilized with ethanol (400 μl of 150 mM NaCl, 850 μl of 100% ethanol) for 30 min on ice, and then fixed (1% paraformaldehyde and 0.1% Tween 20 in Hank’s balanced salt solution) overnight at 4 °C. After permeabilization, cells were treated with 30 μg DNAse for 1 h at 37 °C, stained with Alexa 647-labeled anti-bromodeoxyuridine antibody (Invitrogen, Grand Island, NY, USA) for 1 h at room temperature, and 4',6-diamidino-2-phenylindole was added before analysis with flow cytometry. For Annexin V staining, cells were incubated with an Annexin V-Cy5 antibody (BioVision, Milpitas, CA, USA) in staining buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) for 10 min. The viability dye Sytox-blue (Invitrogen) was added before the cells were assayed for apoptosis and necrosis by flow cytometry. Flow cytometry was performed on an LSRII (Becton Dickinson, San Jose, CA, USA), and data were analyzed with FlowJo software (Tree Star, Ashland, OR, USA).

Patient samples

Use of MF samples was approved by the institutional review boards at Northwestern University and the Mayo Clinic. Peripheral blood was collected from PMF patients in EDTA tubes and mononuclear cells were separated on a ficoll gradient. Mononuclear cells were washed with serum-free Iscove’s modified Dulbecco’s medium and depleted of red cells before CD34+ cells were purified by immunomagnetic beads conjugated with anti-CD34 antibody (Miltenyi Biotec, Auburn, CA, USA). CD34+ cells were cultured in hematopoietic progenitor growth medium in the presence of recombinant human stem cell factor (25 ng/ml), thrombopoietin (20 ng/ml) and FLT-3L (10 ng/ml) for 48 h to allow expansion. CFU-M and BFU-E (1500 cells) or CFU-MK (5000 cells) were then plated in methylcellulose-based colony assays (Methocult H4435, Stem Cell Technologies, Vancouver, BC, Canada) in the presence of 1–10 μM MK-2206 or dimethyl sulfoxide (0.1%) and scored for CFU-GM and BFU-E colonies on days 11–12, respectively. In parallel, 5 × 103 CD34+ cells were plated in CFU-MK colony assays in collagen-based media (Megacult-C #04901, Stem Cell Technologies) in chamber slides in the presence of 1–10 μM MK-2206 or dimethyl sulfoxide (0.1%) and scored after 14 days by staining with an anti-CD41 antibody. The levels of significance for the differential sensitivities of PMF versus normal cell colony assays were determined by analysis of covariance.

Murine model of MPN

The MPLW515L bone marrow transplants were performed as previously described.10 Briefly, bone marrow cells were collected from 5-fluorouracil pretreated female Balb/c donor mice and transduced with viral supernatants containing MSCV-MPLW515L-GFP. Bone marrow cells (500 000) were then injected into the tail veins of irradiated recipient mice along with 100 000 support cells from healthy Balb/c mice. Tail bleeds were performed at day 21 to document disease as measured by >50% green fluorescent protein (GFP) positivity in the peripheral blood and elevated white blood cell counts. Mice were then randomized into three groups (n=8 per group) and treated with vehicle or MK-2206 at 60 mg/kg or 120 mg/kg for 2 weeks and then euthanized. The drug was administered by oral gavage once daily on a Monday-Wednesday-Friday schedule. All mice were treated for 14 days or until any one of several criteria for euthanizing was met, including severe lethargy or loss of >20% of body weight. After killing, peripheral blood was collected and peripheral counts were measured on a HemaVet 950FS (Drew Scientific, Dallas, TX, USA). The sternum, liver and spleen samples were fixed in formalin and then embedded in paraffin for histopathology. Hematoxylin and eosin staining was performed by the pathology core. Immunohistochemistry was performed for von Willebrand factor using the Dako (Carpinteria, CA, USA) A0082 antibody. For flow cytometry, the bone marrow and spleen cells were washed and stained in phosphate-buffered saline+0.1% BSA buffer. Antibodies used included CD41-DyLight 649 (Emfret, Elbelstadt, Germany), CD42-PE (Emfret), Mac1-APC and Gr1-PE (BD Bioscience, San Jose, CA, USA). A separate cohort of nine mice was transplanted with malignant cells for pharmacodynamic studies. These mice were randomized into three groups (n=3 per group) and treated with vehicle or MK-2206 at 60 mg/kg or 120 mg/kg for 1 week, and then euthanized 24 h after the last dose. Whole bone marrow and spleen lysates were used for western blot analysis. Three other cohorts of four mice each were treated with vehicle or MK-2206 at 60 mg/kg or 120 mg/kg for 2 weeks, and then euthanized 24 h after the last dose to evaluate the effect on hematopoiesis in healthy animals. Animal studies were approved by the Northwestern University Institutional Animal Care and Use Committee.


MK-2206 induces cell cycle arrest and apoptosis in JAK2V617F cell lines

MK-2206, a highly selective non-ATP competitive allosteric AKT inhibitor,38 is orally bioavailable and has demonstrated excellent tolerability in clinical trials in the solid tumor setting.36 To better understand the consequences of AKT inhibition in MPNs, we cultured human HEL and SET2 cells that harbor the JAK2V617F mutation. We treated these lines with increasing doses of MK-2206 and enumerated live cells at 24 and 48 h, respectively, by trypan blue staining. We found the 50% effective concentration to be 4.1 μM for SET2 cells and 1.0 μM for HEL cells (Figures 1a and b). Next, to determine how MK-2206 reduced the growth of these cell lines, we assayed the effects of this inhibitor on cell cycle distribution, proliferation and induction of apoptosis. We observed a significant induction of necrosis in SET2 cells at doses above 1 μM, as determined by Annexin V/Sytox staining with the percentage of viable cells decreasing to <25% at 5 μM (Figure 1c). HEL cells also showed a dramatic induction of apoptosis and necrosis at doses above 1 μM (Figure 1d). In addition to a significant effect on cell death, we observed a dose-dependent cell cycle G0/G1 block in HEL cells treated with MK-2206, as assayed by bromodeoxyuridine staining (Figure 1e). Together, these results suggest that induction of apoptosis and cell cycle arrest are an important basis of the observed cellular effect of MK-2206 in the HEL and SET2 cell lines.

Figure 1

MK-2206 inhibits cell growth by inducing cell cycle arrest and apoptosis in HEL and SET2 cells. SET2 (a) and HEL (b) cells were cultured with a range of doses of MK-2206 from 0 to 10 μM. Live cells were enumerated at 48 h using trypan blue staining and the 50% effective concentration (EC50) was calculated using Graph-Prism software. (c, d) Induction of apoptosis and necrosis across a range of concentrations of MK-2206 was assessed in SET2 (c) and HEL (d) cells at 24 h using Annexin V surface expression and Sytox-blue permeability dye. Means±s.d. are shown, n=3. (e) Bromodeoxyuridine (BrdU)/4',6-diamidino-2-phenylindole (DAPI) staining of viable HEL cells treated with MK-2206 for 24 h at concentrations from 0 to 10 μM. Representative plots (left) and bar graph of means (n=4) ±s.e.m. (right) are shown. **P<0.01.

MK-2206 inhibits PI3K/AKT signaling in MPN cells

To assess the effects of AKT inhibition on signaling pathways, we extracted protein from HEL cells and primary human CD34+ cells from a PMF patient, treated the cells with MK-2206 and then performed western blot analysis. Treatment of HEL cells with MK-2206 for 6 h blunted phosphorylation of AKT at concentrations as low as 1 μM (Figure 2a). Concomitant with the striking decrease in p-AKT, we also observed inhibition of the downstream signaling molecule pPRAS-40. There was also a decrease in the phosphorylated form of the pro-apoptotic protein BAD, whose phosphorylation at Ser136 is dependent on the PI3K/AKT pathway. Dephosphorylation of BAD is required for its release from sequestration and induction of apoptosis. Of note, we also saw diminished p-AKT levels in peripheral blood CD34+ cells obtained from a PMF patient after exposure to a 1- and 5-μM MK-2206 for 6 h. This result confirms that MK-2206 targets AKT in human MPN cells (Figure 2b).

Figure 2

Treatment with MK-2206 reduced the level of PI3K-AKT signaling in MPN cells. (a) HEL cells were treated with increasing concentrations of MK-2206 for 6 h and extracts from these cells were subjected to immunoblot analysis for phosphorylated (p) or total forms of proteins associated with the PI3K/AKT signaling pathways. (b) AKT phosphorylation was assessed in PMF CD34+ cells treated with 1 and 5 μM of MK-2206 after 6 h.

Sensitivity of human MPN progenitors to MK-2206

We next cultured peripheral blood CD34+ cells from PMF patients harboring the JAK2V617F mutation or mobilized CD34+ cells from healthy individuals in methylcellulose assays in the presence of a dose titration of MK-2206. We found that exposure of these cells to MK-2206 led to a dose-dependent inhibition of colony formation (Figure 3). Interestingly, while we observed that CFU-M derived from PMF cells were significantly more sensitive than their normal counterparts (P=0.022), and BFU-E from PMF tended to be more sensitive (P=0.068), CFU-MK formation was inhibited in PMF and control cells in a similar fashion. These findings suggest that megakaryocytes are more dependent on AKT signaling than other lineages. This observation is consistent with the existence of crucial crosstalk between AKT and Notch in megakaryocyte specification.39

Figure 3

AKT inhibition by MK-2206 suppressed the growth of myeloid, erythroid and megakaryocytic colonies. Assays for CFU-M (left), BFU-E (middle) and CFU-MK (right) were performed with a series of PMF and control specimens in the presence of 1–10 μM MK-2206. The experiment shows the average ±s.d. for three independent samples for duplicate experiments performed on three PMF and three control CD34+ cells. P-values for the difference in sensitivity between PMF and controls: CFU-M, P=0.022; BFU-E, P=0.069; CFU-MK, P=0.47.

MK-2206 reduces disease burden in a mouse model of MF

To assess the in vivo efficacy of MK-2206, we first evaluated the impact of the drug on hematopoiesis in healthy Balb/c mice (n=4) at doses of 60 and 120 mg/kg and compared the phenotype to vehicle-treated controls. After 2 weeks of treatment, the mice were healthy with no changes in body weight and no changes in peripheral blood counts (Supplementary Fig S1). These results are consistent with human phase I/II data that show that MK-2206 is not myelosuppressive.36 This result also indicates that although CFU-MK was inhibited by MK-2206, treatment of healthy mice did not result in thrombocytopenia.

We next tested whether MK-2206 is efficacious in an in vivo model of MPLW515L-associated MPN. Transplantation of MPLW515L expressing Balb/c hematopoietic progenitor cells into lethally irradiated recipient mice leads to a phenotype that has several features in common with PMF, including peripheral leukocytosis, hepatosplenomegaly, megakaryocyte expansion and reticulin deposition in the marrow and sites of extramedullary hematopoiesis.10 At day 21 after transplantation, the mean white blood cell count for the entire cohort exceeded the normal range for Balb/c mice. Mice were then randomized into three groups (n=8 per group) and treated with vehicle or MK-2206 at 60 or 120 mg/kg for 2 weeks by oral gavage once daily on a Monday-Wednesday-Friday schedule. After 2 weeks of treatment, mice were euthanized and evaluated for disease. Treatment with MK-2206 led to a significant reduction in the liver and spleen size in the higher-dose treatment group compared with vehicle-treated mice (Figure 4a). Treatment also resulted in a reduction in the median white blood cell count in the peripheral blood from 73.6 × 103/dl in the vehicle-treated group to 20.4 × 103/dl in the 60 mg/kg dosed group and 18.9 × 103/dl in the 120 mg/kg dosed group (Figure 4b). Two of the treated animals displayed white blood cell counts much higher than other mice in the study for reasons we do not understand. If these outliers were excluded, the differences between the treated and untreated groups would be statistically significant (P=0.043, Mann–Whitney test). Staining of peripheral smears confirmed a reduction in circulating immature erythroid cells and granulocytes (Figure 4c). These biological effects correlated well with the pharmacodynamic effect of the drug assessed by immunoblot, showing inhibited phosphorylation of AKT at Ser473 and Thr308 in the bone marrow of MPLW515L-transduced mice treated with MK-2206 at 60 and 120 mg/kg for 7 days (Figure 4d). Platelet and red cell counts, as well as the body weights remained largely constant throughout the experiment (Supplementary Fig S2).

Figure 4

MK-2206 reduces MPN disease burden in vivo. Balb/c recipients of the bone marrow donor cells expressing MPLW515L were divided into three groups and treated with captisol (vehicle control), 60 mg/kg MK-2206 or 120 mg/kg MK-2206 (n=8 per group) by oral gavage three times a week on a Monday-Wednesday-Friday schedule. Mice were killed after 14 days of therapy and disease burden was assessed. (a) Liver and spleen weights of treatment groups. Means±s.d. are shown, n=8. P-values represent spleen/liver weights in 120 mg/kg group versus weights of vehicle-treated mice. (b) White blood cell count (WBC) of mice from the three groups after 14 days of therapy, median values are highlighted in red. (c) May–Grunwald–Giemsa-stained peripheral blood smears of control and MK-2206-treated animals (40 × ). (d) Western blot analysis of MPLW515L whole bone marrow demonstrated abrogation of AKT phosphorylation after 7 days of MK-2206 treatment (60 and 120 mg/kg).

MK-2206 inhibits megakaryocyte expansion in MPLW515L-recipient mice

The composition of the bone marrow and spleen of MPLW515L recipients treated with vehicle or MK-2206 were analyzed by flow cytometry after staining for myeloid precursors with Mac-1 and Gr-1, and megakaryocytes with CD41 antibodies. We observed an expansion of CD41+ cells in the bone marrow of transplanted mice that was significantly reduced by MK-2206 treatment (Figures 5a and b). In contrast, no significant changes were seen in the mature myeloid populations in the bone marrow after treatment for 14 days (Figure 5b). Histological evaluation of the bone marrow, liver and spleen revealed extensive extramedullary hematopoiesis with effacement of liver and spleen architecture and hypercellular bone marrow with granulocyte hyperplasia in transplanted mice. It is noteworthy that there was a visible reduction in megakaryocytic expansion in the liver, spleen and bone marrow of mice that received the higher dose of 120 mg/kg MK-2206 (Figures 5c–e). This effect was confirmed by immunohistochemical staining with an antibody against von Willebrand factor. In addition, we performed reticulin staining on the bone marrow slides, which were scored on a scale ranging from 0–3 independently by a pathologist who was blinded to the randomization groups (SG). We noted a reduction in the severity of fibrosis with vehicle-treated mice exhibiting an average score of 1, whereas the 120 mg/kg MK-2206 treatment group score reduced to 0.57 (n=7 mice per group). It is noteworthy that none of the drug-treated mice had a score >1, whereas grade 2 fibrosis was seen in 2/8 vehicle-treated mice.

Figure 5

MK-2206 reduces the megakaryocyte burden in a mouse model of PMF. Cells from bone marrows of MPLW515L recipients treated with captisol (vehicle control), 60 mg/kg MK-2206 or 120 mg/kg MK-2206 for 14 days were collected and stained with fluorescently conjugated antibodies against CD41or Mac1/Gr1. (a) Representative flow cytometry plots. (b) Bar graphs depicting mean±s.e.m. of the bone marrow megakaryocytes and myeloid cells (n=7 mice per group, P=0.05). Two mice were excluded from the analysis owing to poor engraftment. (ce) Histological sections of the liver (c), spleen (d) and bone marrow (e) after 14 days of treatment. Scale bars represent 25 μM. The upper row represents hematoxylin and eosin (H&E) staining and the lower row displays immunohistochemical staining of von Willebrand factor (vWF). Arrows highlight the megakaryocytes in the H&E sections. Reticulin staining of the bone marrow is shown in the bottom panels.

MK-2206 synergizes with the JAK inhibitor ruxolitinib in MPN cells

Given the toxicities of ruxolitinib on erythroid cells and megakaryocytes and the absence of this effect of MK-2206 in our mouse study, use of a lower dose of a JAK inhibitor in combination with MK-2206 may have a more beneficial effect in patients. To investigate the potential for combining these therapies, we cultured SET2 cells with a range of doses of ruxolitinib and MK-2206 spanning the 50% effective concentration for both drugs, and then counted live cells by trypan blue exclusion. At all doses tested, the combination was synergistic, based on combination index calculations (Figure 6a; note combination index <1 indicates synergy). Co-treatment with MK-2206 and ruxolitinib synergistically induced apoptosis and necrosis of the SET 2 cells (Figure 6b). These data suggest that combining these two agents may provide therapeutic efficacy at lower doses of ruxolitinib.

Figure 6

MK-2206 and ruxolitinib synergize to inhibit growth of JAK2V617-mutant SET2 cells. (a) All combinations of MK-2206 and ruxolitinib tested give rise to strong synergy as evidenced by combination index (CI) value. Fa, fraction of cells affected by the drugs. Data are representative of three independent replicates. (b) The combination of 500 nM MK-2206 and 125 nM ruxolitinib, which alone do not show much of an effect on SET2 cell viability, synergize to give rise to robust cell death as measured by Annexin V staining. Representative plots of three independent biological replicates are shown.


In preclinical studies, JAK2 inhibitors reduced the proliferation of JAK2V617F and MPLW515L mutant cells and attenuated disease development in murine models of MPN.40, 41, 42, 43 Early clinical trials in patients with MF resulted in clinical improvement, although the effects on the burden of JAK2-mutant clone were less impressive than anticipated.8, 22, 44 Moreover, given that JAK2 is essential for normal hematopoiesis,45 treatment with JAK2 inhibitors has been limited by hematological toxicities, including anemia and thrombocytopenia.

With the realization that ruxolitinib, although effective at relieving many symptoms of MF, is not a cure for MPNs, there is a great interest in the development of improved JAK2 inhibitors and combinatorial therapies that target the disease. Compounds that have demonstrated single-agent efficacy in clinical trials include immunomodulators such as pomalidomide,46 which alleviates the anemia associated with MF and drugs that affect remodeling of chromatin such as Givinostat.47, 48 Preclinical studies of other histone deacetylase inhibitors, including panobinostat, for MPN have also shown promising results but have been associated with myelosuppression, in particular thrombocytopenia.28, 49 Oncoproteins such as JAK2V617F are dependent on the chaperone function of heat shock protein 90, and this has also been validated as a therapeutic target in MPNs.50, 51 Moreover, in a recent phase I/II study of the mammalian target of rapamycin (mTOR) inhibitor everolimus, patients with MF showed improvement in splenomegaly, systemic symptoms and pruritus, reproducing many of the effects seen with JAK inhibitors.52 Myelosuppression was modest, and hematological toxicity was mainly represented by a grade 2/3 reversible decrease of hemoglobin. It is noteworthy that in preclinical studies other groups have found that PI3K/mTOR inhibitors show effective against MPN cells alone and in combination with ruxolitinib.31, 32

The PI3K/AKT pathway is frequently activated in human cancers and has a critical role in cell growth, proliferation, survival, apoptosis and autophagy.53 Here we confirm that the PI3K/AKT pathway is activated in the MPNs downstream of both JAK2V617F and MPLW515L, and further, that MPN cells are dependent on this pathway for proliferation, survival and clonogenic expansion. The novel allosteric AKT inhibitor MK-2206 has demonstrated cytotoxic activity against T-ALL cell lines and patient primary cells54 and synergism with epidermal growth factor receptor inhibitors, such as erlotinib or lapatinib in breast cancer cells,38 with gefitinib in malignant glioma55 and with MEK inhibitors in non-small cell lung cancers.56 The added benefit of an allosteric inhibitor of AKT rather than an ATP-competitive inhibitor is reduced off-target effect. Indeed, the first phase I trial of this drug in solid tumors showed no hematological toxicity and was very well tolerated.36 It is noteworthy that we observed no overt hematological toxicity with MK-2206 in healthy mice. Our studies further demonstrate that MK-2206 synergizes with the JAK kinase inhibitor ruxolitinib in vitro in a JAK2V617F-mutant cell line.

MPNs are characterized by extramedullary hematopoiesis with abnormal megakaryocyte morphology and hyperplasia. PMF hematopoietic progenitor cells have demonstrated an increased ability to generate megakaryocytes and a decreased rate of apoptosis.57 In our studies, MK-2206 dramatically suppressed megakaryocyte colony formation from PMF CD34+ cells, although it also showed activity against CFU-MK from healthy progenitors. We surmise that this is owing to a strong requirement for AKT in megakaryocyte specification.39 MK-2206 also shows activity against megakaryocytic leukemia cell lines.58 It is noteworthy that selectivity for MK-2206 on malignant hematopoiesis has been noted by others, such as one study that found MK-2206 had a minimal effect on the proliferation of peripheral blood CD4+ T cells and clonogenic potential of cord blood CD34+ cells from healthy donors.54 Moreover, in our murine model of MPLW515Linduced MF, treatment with MK-2206 decreased extramedullary hematopoiesis, reduced megakaryocyte expansion in the bone marrow and reduced the severity of reticulin fibrosis in the marrow without inducing peripheral cytopenias. Moreover, this same treatment course had no overt effect on hematopoiesis in healthy mice.

Together, our findings establish AKT as a rational therapeutic target for the treatment of patients with MPNs. As we become cognizant of the limitations of anti-JAK therapy, inhibition of AKT kinase activity may emerge as an important therapeutic option. Finally, because MK-2206 has already shown excellent tolerability in phase I trials for solid tumors, clinical trials of MK-2206 in combination with ruxolitinib should be considered in MPN patients.


  1. 1

    Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA . Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol 2008; 83: 359–362.

  2. 2

    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

  3. 3

    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

  4. 4

    James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.

  5. 5

    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

  6. 6

    Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280: 22788–22792.

  7. 7

    Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

  8. 8

    Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117–1127.

  9. 9

    Tefferi A . Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? Leukemia 2011; 25: 1059–1063.

  10. 10

    Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.

  11. 11

    Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112: 141–149.

  12. 12

    Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG . Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274–4281.

  13. 13

    Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006; 1: e18.

  14. 14

    Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL . JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652–1660.

  15. 15

    Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010; 17: 584–596.

  16. 16

    Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia 2011; 25: 1834–1839.

  17. 17

    Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289–2301.

  18. 18

    Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183–2186.

  19. 19

    Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; e-pub ahead of print 17 May 2013; doi:10.1038/leu.2013.119.

  20. 20

    Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 2012; 26: 1135–1137.

  21. 21

    Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.

  22. 22

    Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789–796.

  23. 23

    Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013; 27: 1322–1327.

  24. 24

    Tefferi A . JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012; 119: 2721–2730.

  25. 25

    Ugo V, Marzac C, Teyssandier I, Larbret F, Lecluse Y, Debili N et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004; 32: 179–187.

  26. 26

    Laubach JP, Fu P, Jiang X, Salter KH, Potti A, Arcasoy MO . Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp Hematol 2009; 37: 1411–1422.

  27. 27

    Grimwade LF, Happerfield L, Tristram C, McIntosh G, Rees M, Bench AJ et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 2009; 147: 495–506.

  28. 28

    Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009; 114: 5024–5033.

  29. 29

    Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG . Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115: 3589–3597.

  30. 30

    Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008; 118: 3038–3050.

  31. 31

    Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A et al. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS One 2013; 8: e54826.

  32. 32

    Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S et al. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther 2013; 12: 577–588.

  33. 33

    Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010; 16: 5424–5435.

  34. 34

    Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010; 70: 8097–8107.

  35. 35

    Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30: 282–290.

  36. 36

    Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011; 29: 4688–4695.

  37. 37

    Uozumi K, Otsuka M, Ohno N, Moriyama T, Suzuki S, Shimotakahara S et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia 2000; 14: 142–152.

  38. 38

    Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956–1967.

  39. 39

    Cornejo MG, Mabialah V, Sykes SM, Khandan T, Lo Celso C, Lopez CK et al. Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. Blood 2011; 118: 1264–1273.

  40. 40

    Wernig G, Kharas MG, Mullally A, Leeman DS, Okabe R, George T et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia 2012; 26: 720–727.

  41. 41

    Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 2010; 115: 2919–2927.

  42. 42

    Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115: 5232–5240.

  43. 43

    Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658–1668.

  44. 44

    Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010; 115: 1131–1136.

  45. 45

    Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385–395.

  46. 46

    Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011; 25: 301–304.

  47. 47

    Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008; 22: 740–747.

  48. 48

    Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010; 150: 446–455.

  49. 49

    Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol 2013; 161: 68–75.

  50. 50

    Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010; 120: 3578–3593.

  51. 51

    Fiskus W, Verstovsek S, Manshouri T, Rao R, Balusu R, Venkannagari S et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res 2011; 17: 7347–7358.

  52. 52

    Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011; 118: 2069–2076.

  53. 53

    Engelman JA . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550–562.

  54. 54

    Simioni C, Neri L, Tabellini G, Ricci F, Bressanin D, Chiarini F et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26: 2336–2342.

  55. 55

    Cheng Y, Zhang Y, Zhang L, Ren X, Huber-Keener KJ, Liu X et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 2012; 11: 154–164.

  56. 56

    Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 2010; 5: e14124.

  57. 57

    Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007; 110: 986–993.

  58. 58

    Stankiewicz MJ, Crispino JD . AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL. Leukemia 2013; 27: 1339–1347.

Download references


We thank Jonathan Licht and Lou Dore for their helpful advice and critical reading of the manuscript. We also thank Merck for supplying MK-2206. This work was supported in part by grants from the NIH (CA101774 to JDC) and the Leukemia and Lymphoma Society, the Samuel Waxman Cancer Research Foundation, National Natural Science Foundation of China (Grant No. 30700412 and 81070406 to Z Huang). IK was supported by a T32 Grant to Northwestern University. IK is a recipient of the American Society of Hematology Translational Research Training in Hematology (TRTH) Award.

Author information

Correspondence to A Tefferi or J D Crispino.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author Contributions

IK, ZH, QW, LG, BG performed the experiments, analyzed the data and wrote the manuscript. PK, LD, MJS and RS assisted with experiments and animal studies. SG analyzed the data and assisted with the manuscript. CF, TL, QW, MS, AP, BS, JA and AT assisted with patient specimen experiments. RL, AT and JC analyzed the data and wrote the manuscript.

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Khan, I., Huang, Z., Wen, Q. et al. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia 27, 1882–1890 (2013) doi:10.1038/leu.2013.167

Download citation


  • myelofibrosis
  • PI3K
  • MPL
  • JAK2

Further reading